Agilent expects expanded Frederick plant to break ground this month, deliver product by 2026
FREDERICK — California-based life-sciences company Agilent Technologies Inc. expects to break ground this month on its Frederick manufacturing facility expansion and begin shipments of pharmaceutical ingredients from its new production lines by 2026.
The Weld Count plant, for which the company will receive state and local subsidies for a $725 million expansion effort, is developing therapeutic nucleic acids, known as therapeutic oligonucleotides or oligos.
Those oligos “will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules,” the company said Monday.
Oligo technology has been around for more than 20 years, but pharmaceutical companies only recently have begun…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Enliven Therapeutics finished the third quarter with $292 million in cash, which, the company said,…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Arca Biopharma has completed its merger with Oruka Therapeutics Inc.
